Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human EHD2 Antibodies:
anti-Mouse (Murine) EHD2 Antibodies:
anti-Rat (Rattus) EHD2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal EHD2 Primary Antibody for ELISA, WB - ABIN250284
Guilherme, Soriano, Furcinitti, Czech: Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. in The Journal of biological chemistry 2004
Human Polyclonal EHD2 Primary Antibody for IHC, IHC (p) - ABIN4307515
Kim, Kim, Jeon, Kim, Kim, Bae, Jung: Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma. in PLoS ONE 2017
Our prognostic model is useful for predicting persistent/recurrent disease after surgery of Papillary thyroid carcinoma (PTC (show F9 Antibodies)). EHD2 mRNA expression could be a novel prognostic marker for PTC (show F9 Antibodies) patients.
EHD2 expression, along with the epithelial marker E-cadherin (show CDH1 Antibodies), was markedly reduced in tumor tissues than in adjacent noncancerous tissues. Molecular data indicated that EHD2 inhibited migration and invasion of hepatocellular carcinoma probably by interacting with E-cadherin (show CDH1 Antibodies).
Data suggest that the EH-domain containing 2 protein (EHD2) NPF phenylalanine residue is crucial for EHD2 localization to the plasma membrane, whereas the proline residue is essential for EHD2 dimerization and binding.
EHD2 can inhibit the metastasis of human breast cancer by regulating the epithelial-to-mesenchymal transition markers E-cadherin (show CDH1 Antibodies) and N-cadherin (show CDH2 Antibodies).
Downregulation of EHD2 was associated with migration and invasion by abrogating the expression of Rac1 (show RAC1 Antibodies) in breast cancer patients.
Phosphatidylinositol 4,5-bisphosphate controls EHD2 plasma membrane localization.
Our results suggested that EHD2 low expression is involved in the pathogenesis of human esophageal squamous cell carcinoma
EHD2 participates in the sarcolemma repair.
Assembly of EHD2 stabilized and constrained caveolae to the plasma membrane to control turnover, and depletion of EHD2, resulting in endocytic and more dynamic and short-lived caveolae.
Among three EHD proteins (EHD1-EHD3 (show EHD3 Antibodies)) that were tested, only EHD2 accumulates in the nucleus under nuclear export inhibition treatment.
EHD2 (show EHD3 Antibodies) may be cardioprotective as a dominant-negative EHD2 (show EHD3 Antibodies) mutant sensitized cardiomyocytes to ischemic damage. Our findings highlight EHD2 (show EHD3 Antibodies) as a potential pharmacologic target in the treatment of diseases with KATP channel trafficking defects
EHD1 (show EHD1 Antibodies), EHD2 (show EHD3 Antibodies), and EHD4 (show EHD4 Antibodies) are recruited to caveolae. Recruitment of the other EHDs increases markedly when EHD2 (show EHD3 Antibodies), which has been previously detected at caveolae, is absent. Construction of knockout cell lines lacking EHDs 1, 2, and 4 confirms this apparent functional redundancy.
The regulatory N-terminal residues and the EH domain keep the EHD2 (show EHD3 Antibodies) dimer in an autoinhibited conformation in solution. By significantly advancing the use of infrared reflection-absorption spectroscopy, we demonstrate that EHD2 (show EHD3 Antibodies) adopts an open conformation by tilting the helical domains upon membrane binding.
The helical domain of EHD2 (show EHD3 Antibodies) is inserted into the membrane.The N terminus domain regulates caveolar targeting of EHD2 (show EHD3 Antibodies).
Assembly of EHD2 (show EHD3 Antibodies) stabilized and constrained caveolae to the plasma membrane to control turnover, and depletion of EHD2 (show EHD3 Antibodies), resulting in endocytic and more dynamic and short-lived caveolae.
The characterization of Fer1L5 and its interaction with EHD1 (show EHD1 Antibodies) and EHD2 (show EHD3 Antibodies) underscores the complex requirement of ferlin proteins and mediators of endocytic recycling for membrane trafficking events during myotube formation
appears to connect endocytosis to the actin cytoskeleton through interactions of its N-terminal domain with membranes and its C-terminal EH domain with the novel EHBP1 (show EHBP1 Antibodies) protein
interaction of myoferlin (show MYOF Antibodies) with EHD2 (show EHD3 Antibodies) identifies molecular overlap between the endocytic recycling pathway and the machinery that regulates myoblast membrane fusion
This gene encodes a member of the EH domain-containing protein family. These proteins are characterized by a C-terminal EF-hand domain, a nucleotide-binding consensus site at the N terminus and a bipartite nuclear localization signal. The encoded protein interacts with the actin cytoskeleton through an N-terminal domain and also binds to an EH domain-binding protein through the C-terminal EH domain. This interaction appears to connect clathrin-dependent endocytosis to actin, suggesting that this gene product participates in the endocytic pathway.
EH domain containing 2
, EH domain-containing protein 2
, PAST homolog 2
, putative eps protein
, EH-domain containing 2
, EH-domain containing 1
, EH-domain-containing protein 2
, EH domain-containing protein 2-like